Eris Lifesciences Ltd (ERIS) AI Stock Analysis

• Market Cap: ₹187.13B
• Dividend Yield: 0.47%
• Average Volume (3M): 2.07K
• Price to Earnings (P/E): 45.0
• Beta (1Y): 0.61
• Revenue Growth: 20.02%
• EPS Growth: 19.17%
• Country: IN
• Employees: 3,620
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 8.80
• Shares Outstanding: 136,216,890
• 10 Day Avg. Volume: 1,915
• 30 Day Avg. Volume: 2,071
• PEG Ratio: -5.23
• Price to Book (P/B): 6.64
• Price to Sales (P/S): 6.58
• P/FCF Ratio: 20.82
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 70 Outperform
• Price Target: ₹1,511.00 ▼(-1.30% Downside)

Eris Lifesciences Ltd demonstrates strong financial performance with robust revenue and cash flow growth, which significantly contributes to the overall score. The technical analysis shows a positive trend, though some bearish signals are present. The high P/E ratio and low dividend yield suggest overvaluation, impacting the valuation score.

Positive Factors

Chronic-therapy focus

Concentration in cardiometabolic and other chronic, lifestyle-linked therapies creates recurring prescription demand and higher patient stickiness. Over months this supports predictable volume streams, stable revenue cadence, and stronger lifetime value per brand versus acute care products.

Consistent top-line and EPS growth

Sustained ~20% revenue growth with similar EPS expansion indicates growing market acceptance and improving operational leverage. This trend supports durable cash generation, funds reinvestment in sales/marketing, and capacity expansion without relying on transient market conditions.

Robust margins and operating efficiency

Strong gross and EBITDA margins reflect disciplined cost management and pricing power in branded formulations. Durable margin structure supports cash flow conversion, funds R&D or sales expansion, and provides buffer against input-cost fluctuations over the medium term.

Negative Factors

Free cash flow volatility

Variable FCF reduces predictability for capex, acquisitions, or shareholder returns. Even with improving averages, recurring volatility can force conservative cash retention or incremental borrowing, limiting strategic spending flexibility over the next several quarters.

Declining cash balances

A trend of falling cash and equivalents weakens liquidity cushions and reduces the firm’s ability to absorb shocks or opportunistically invest. Persistent declines could necessitate external financing or curtailment of discretionary investment within a multi-quarter horizon.

Dependence on physician-facing branded model

Heavy reliance on brand acceptance and an active salesforce requires ongoing high marketing and field investments to defend share. Market access and pricing dynamics (including regulatory/price-control risks in India) can pressure margins and growth if prescriber preferences or regulation shift.

Eris Lifesciences Ltd Business Overview & Revenue Model

Company Description

Eris Lifesciences Limited manufactures, markets, and distributes pharmaceutical products in India. It offers various branded formulations in various therapeutic areas, such as cardiovascular, anti–diabetes, anti-infective, antipyretics, vitamins/nutrients, gastroenterology, respiratory, gynecology, pediatrics, neurology, psychiatry, and pain/analgesics, as well as in-vitro fertilization, cosmetology, and dermatology. Eris Lifesciences Limited was incorporated in 2007 and is based in Ahmedabad, India.

How the Company Makes Money

Eris Lifesciences generates revenue primarily through the sales of its pharmaceutical products, particularly its branded generics. The company has a well-established distribution network that allows it to reach a broad customer base, including hospitals, pharmacies, and healthcare providers across India. Key revenue streams include prescription drugs for chronic diseases, which are often prescribed by healthcare professionals, and a range of over-the-counter medications. Additionally, ERIS may engage in partnerships with other pharmaceutical companies for co-marketing or distribution agreements, further enhancing its market reach and revenue potential. Factors contributing to its earnings include a strong focus on research and development to innovate new products, strategic marketing initiatives, and maintaining a robust supply chain to ensure product availability.

Eris Lifesciences Ltd Financial Statement Overview

Summary

Eris Lifesciences Ltd displays solid financial health with strong revenue and cash flow growth. The company effectively manages its operational and financial resources, evidenced by robust margins and a solid equity base. However, areas such as cash balances and Free Cash Flow volatility need monitoring.

Income Statement

Eris Lifesciences Ltd has shown impressive revenue growth over the years, with a significant jump from 2024 to 2025. The Gross Profit Margin remains strong, indicating efficient cost management. However, the Net Profit Margin has shown some fluctuations, indicating potential areas for improvement. The EBIT and EBITDA margins are robust, demonstrating solid operational efficiency.

Balance Sheet

The company maintains a healthy balance sheet with a solid equity base. The Debt-to-Equity Ratio is manageable, suggesting prudent financial leverage. The Return on Equity is strong, reflecting effective resource utilization. However, the decrease in cash and equivalents over the years may need monitoring.

Cash Flow

Eris Lifesciences Ltd has demonstrated strong growth in Operating Cash Flow, which supports its Net Income. The Free Cash Flow has seen significant improvement, indicating efficient capital expenditure management. However, the fluctuations in Free Cash Flow over the years highlight potential volatility in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	29.37B	28.79B	19.91B	16.62B	13.26B	11.93B
Gross Profit	20.13B	21.49B	9.95B	13.09B	10.65B	9.51B
EBITDA	10.58B	10.17B	6.99B	5.48B	5.11B	4.39B
Net Income	3.87B	3.52B	3.92B	3.82B	4.06B	3.55B
Balance Sheet
Total Assets	0.00	70.33B	70.49B	36.67B	22.72B	18.35B
Cash, Cash Equivalents and Short-Term Investments	2.05B	2.28B	13.39B	892.43M	2.12B	1.31B
Total Debt	0.00	24.78B	27.81B	8.77B	844.07M	67.77M
Total Liabilities	-32.72B	37.61B	38.27B	14.47B	3.64B	2.58B
Stockholders Equity	32.72B	28.54B	25.86B	21.96B	19.08B	15.76B
Cash Flow
Free Cash Flow	0.00	9.10B	3.57B	-5.50B	2.57B	3.50B
Operating Cash Flow	0.00	10.65B	4.86B	2.92B	3.78B	3.75B
Investing Cash Flow	0.00	-799.70M	-18.55B	-9.82B	-3.20B	-3.23B
Financing Cash Flow	0.00	-8.81B	13.80B	6.88B	-446.99M	-823.95M

Eris Lifesciences Ltd Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1530.85
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:ERIS, the sentiment is Negative. The current price of 1530.85 is above the 20-day moving average (MA) of 1443.11, above the 50-day MA of 1522.11, and below the 200-day MA of 1609.49, indicating a bearish trend. The MACD of -50.04 indicates Positive momentum. The RSI at 34.97 is Neutral, neither overbought nor oversold. The STOCH value of 24.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:ERIS.

Eris Lifesciences Ltd Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ERIS	70 Outperform	₹187.13B	45.01	―	0.47%	20.02%	19.17%
GLAND	63 Neutral	₹304.07B	35.89	―	1.07%	-1.51%	14.27%
GLAXO	63 Neutral	₹406.14B	42.52	―	2.16%	4.17%	41.51%
GLENMARK	53 Neutral	₹569.17B	53.44	―	0.24%	30.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Eris Lifesciences Ltd Corporate Events

Eris Lifesciences Raises Stake to Make Swiss Parenterals Wholly Owned Unit via Preferential Share Allotment

Eris Lifesciences has allotted 2,306,372 fully paid equity shares of face value Re 1 each at an issue price of ₹1,835.35 per share on a preferential basis via private placement to investor Naishadh Shah, as consideration other than cash. The shares were issued in exchange for 1,674,493 equity shares representing 30% of Swiss Parenterals Ltd, completing Eris’s acquisition of this stake and making Swiss Parenterals a wholly owned subsidiary. Following the allotment, Eris’s paid-up equity capital has risen from ₹13.62 crore to ₹13.85 crore, with the new shares ranking pari passu with existing equity except for regulatory lock-in conditions, and are to be listed on NSE and BSE after receipt of listing approvals, signaling further consolidation of Eris’s manufacturing footprint and control over its injectable/ parenteral capabilities.

Eris Lifesciences Announces Postal Ballot Notice Dispatch

Eris Lifesciences Limited has announced the electronic dispatch of a Notice of Postal Ballot, as published in Financial Express on November 25, 2025. This announcement is part of their compliance with the Securities and Exchange Board of India regulations, ensuring transparency and communication with stakeholders.

Eris Lifesciences Initiates Postal Ballot for Shareholder Resolutions

Eris Lifesciences Ltd has announced a postal ballot to seek approval from its members on certain resolutions via electronic voting. This move aligns with regulatory requirements and facilitates shareholder engagement through digital means, potentially enhancing operational transparency and compliance.

Eris Lifesciences Acquires 30% Stake in Swiss Parenterals

Eris Lifesciences Ltd announced the acquisition of 30% of the share capital of its subsidiary, Swiss Parenterals Limited. To facilitate this acquisition, Eris will issue over 2.3 million equity shares on a preferential basis, which will also involve a material related party transaction with Mr. Naishadh Shah, a director at Swiss Parenterals. This strategic move is expected to enhance Eris’s operational capabilities and strengthen its market position.

Eris Lifesciences Expands Stake in Swiss Parenterals

Eris Lifesciences Ltd’s board has approved the acquisition of a 30% stake in its subsidiary, Swiss Parenterals Limited, by issuing over 2.3 million equity shares on a preferential basis. This strategic move aims to strengthen Eris Lifesciences’ control over its subsidiary, potentially enhancing its market position and operational capabilities.

Eris Lifesciences Announces Investor Call to Discuss Financial Results

Eris Lifesciences Ltd has announced a scheduled conference call for analysts and investors to discuss the company’s unaudited financial results for the quarter and half-year ending September 30, 2025. This call, set for November 12, 2025, is part of the company’s efforts to maintain transparency with stakeholders and provide insights into its financial performance and strategic direction.